Dr. Thomas J. George JR., MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Florida College of Medicine (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 54
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: University of Florida College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
FL license ME79522
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uf Health Shands Hospital Gainesville, FL
Medical groups
- Florida Clinical Practice Association Inc (1,924 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 54
- Services billed
- 164
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 55 | 21 |
| Established patient office or other outpatient visit, 30-39 minutes | 32 | 25 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Gainesville, FL | 18 |
| Imatinib Mesylate | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $2,261 in total to this clinician.
| Pfizer Inc. | $2,100 |
|---|---|
| Regeneron Pharmaceuticals, Inc. | $117 |
| AstraZeneca Pharmaceuticals LP | $43.25 |
| Consulting Fee | $2,100 |
|---|---|
| Food and Beverage | $117 |
| Education | $43.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jun 30, 2025 | Consulting Fee TIVDAK · ONCOLOGY | $2,100 |
| AstraZeneca Pharmaceuticals LP Nov 19, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 8 companies. The companies reported $507,585 in research payments for these studies, mostly to the institutions running them.
- A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT04626635 - A phase 1 study of sgnstnv in advanced solid tumors
Pfizer Inc. - A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation
Astellas Pharma Inc - A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers
E.r. Squibb & Sons, L.l.c. - Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors
Pfizer Inc. - A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT07058012 - Appendix F to the Precision Promise Master Protocol: Canakinumab and Spartalizumab in Combination with Nab-Paclitaxel and Gemcitabine in Subjects with Metastatic Pancreatic Cancer
Novartis Pharmaceuticals Corporation - An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors
Merck Sharp & Dohme LLC - A Phase 1,2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
Merck Sharp & Dohme LLC - A phase 1b,2, multicenter, open-label study of S-531011 as monotherapy and in combination with an immune checkpoint inhibitor in participants with locally advanced or metastatic solid tumors
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.